文献速递主动脉疾病

预防性囊腔流出血管栓塞与腹主动脉瘤腔内修复术后囊腔回缩改善相关

Prophylactic sac outflow vessel embolization is associated with improved sac regression in patients undergoing endovascular aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2021-12-17

基于血管外科学会血管质量倡议数据库2009年1月至2020年11月择期EVAR患者共15060例,比较单纯EVAR(14788例)与联合预防性囊腔流出血管栓塞(emboEVAR,272例)。emboEVAR手术时间、透视时间及造影剂用量显著增加,但中期随访囊腔最大径平均缩小更多(0.69 vs 0.54 cm,P=0.006),囊腔回缩≥5 mm比例更高(53.5% vs 48.7%),II型内漏发生率无显著差异。

要点

  • emboEVAR组中期囊腔最大径平均缩小0.69 cm,单纯EVAR组0.54 cm(P=0.006)。
  • emboEVAR组囊腔回缩≥5 mm比例53.5%,单纯EVAR组48.7%。
  • 两组术后并发症、再干预率及30天死亡率无显著差异。

核心结论

  • 预防性囊腔流出血管栓塞可在择期EVAR的完整腹主动脉瘤患者中安全实施,未伴显著围手术期并发症或死亡。
  • 中期随访时emboEVAR较单纯EVAR与显著囊腔回缩相关,但II型内漏发生率未见下降。
  • 作者认为该技术有前景,未来应聚焦识别可从选择性或完全预防性囊腔流出血管栓塞中获益的动脉瘤及流出分支特征亚组。

研究设计与样本

  • 回顾性分析血管外科学会血管质量倡议数据库2009年1月至2020年11月期间接受择期EVAR的完整腹主动脉瘤患者,年龄≥18岁。
  • 排除既往主动脉修复史及无随访数据的患者。
  • 共纳入15060例,其中emboEVAR组272例,单纯EVAR组14788例。

主要发现

  • 两组年龄、合并症及解剖特征无显著差异,术前平均最大主动脉直径5.5 vs 5.6 cm(P=0.48)。
  • emboEVAR组手术时间148 vs 124分钟(P<0.0001)、透视时间32 vs 23分钟(P<0.0001)、造影剂用量105 vs 91 mL(P<0.0001)均显著高于单纯EVAR组。
  • 病例完成时II型内漏发生率17.7% vs 16.3%(P=0.54),无显著差异。
  • 术后并发症3.7% vs 4.6%(P=0.56)、住院期间再干预0.7% vs 1.3%(P=0.59)、住院时间1.8 vs 2天(P=0.75)、30天死亡率0% vs 0%(P=1.00)两组相似。
  • 中期随访(14.6±6.2个月)emboEVAR组囊腔最大径平均缩小0.69 vs 0.54 cm(P=0.006),囊腔回缩≥5 mm比例53.5% vs 48.7%,再干预率两组相似。

临床怎么用

  • 作者认为预防性囊腔流出血管栓塞可在择期EVAR的完整腹主动脉瘤患者中安全实施。
  • 作者指出该技术有前景,未来应聚焦识别可从选择性或完全预防性囊腔流出血管栓塞中获益的动脉瘤及流出分支特征亚组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type II endoleaks (T2Es), often identified after endovascular aneurysm repair (EVAR), have been associated with late endograft failure and secondary rupture. The number and size of the patent aortic aneurysm sac outflow vessels (ie, the inferior mesenteric, lumbar, and accessory renal arteries) have been implicated as known risk factors for persistent T2Es. Given the technical challenges associated with post-EVAR embolization, prophylactic embolization of aortic aneurysm sac outflow vessels has been advocated to prevent T2Es; however, the evidence available at present is limited. We sought to examine the effects of concomitant prophylactic aortic aneurysm sac outflow vessel embolization in patients undergoing EVAR. METHODS: Patients aged ≥18 years included in the Society for Vascular Surgery Vascular Quality Initiative database who had undergone elective EVAR for intact aneurysms between January 2009 and November 2020 were included in the present study. Patients with a history of prior aortic repair and those without available follow-up data were excluded. The patient demographics, operative characteristics, and outcomes were analyzed by group: EVAR alone vs EVAR with prophylactic sac outflow vessel embolization (emboEVAR). The outcomes of interest were the in-hospital postoperative complication rates, incidence of aneurysmal sac regression (≥5 mm) and T2Es, and reintervention rates during follow-up. RESULTS: A total of 15,060 patients were included. Of these patients, 272 had undergone emboEVAR and 14,788 had undergone EVAR alone. No significant differences were found between the two groups in age, comorbidities, or anatomic characteristics, including the mean maximum preoperative aortic diameter (5.5 vs 5.6 cm; P = .48). emboEVAR was associated with significantly longer procedural times (148 vs 124 minutes; P < .0001), prolonged fluoroscopy times (32 vs 23 minutes; P < .0001), increased contrast use (105 vs 91 mL; P < .0001), without a significant reduction in T2Es at case completion (17.7% vs 16.3%; P = .54). The incidence of postoperative complications (3.7% vs 4.6%; P = .56), index hospitalization reintervention rates (0.7% vs 1.3%; P = .59), length of stay (1.8 vs 2 days; P = .75), and 30-day mortality (0% vs 0%; P = 1.00) were similar between the two groups. At mid-term follow-up (14.6 ± 6.2 months), the emboEVAR group had a significantly greater mean reduction in the maximum aortic diameter (0.69 vs 0.54 cm; P = .006), with a greater proportion experiencing sac regression of ≥5 mm (53.5% vs 48.7%). The reintervention rates were similar between the two groups. On multivariable analysis, prophylactic aortic aneurysm sac outflow vessel embolization (odds ratio, 1.34; 95% confidence interval, 1.04-1.74; P = .024) was a significant independent predictor of sac regression. CONCLUSIONS: Prophylactic sac outflow vessel embolization can be performed safely for patients with intact aortic aneurysms undergoing elective EVAR without significant associated perioperative morbidity or mortality. emboEVAR was associated with significant sac regression compared with EVAR alone at mid-term follow-up. Although no decrease was found in the incidence of T2Es, this technique shows promise, and future efforts should focus on identifying a subset of aneurysm and outflow branch characteristics that will benefit from concomitant selective vs complete prophylactic sac outflow vessel embolization.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Rokosh RS, Chang H, Butler JR, et al. Prophylactic sac outflow vessel embolization is associated with improved sac regression in patients undergoing endovascular aortic aneurysm repair. J Vasc Surg. 2021. PMID: 34923066. doi:10.1016/j.jvs.2021.11.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。